The acyl-CoA-binding protein (ACBP)/diazepam binding inhibitor is an intracellular protein that binds C(14)-C(22) acyl-CoA esters and is thought to act as an acyl-CoA transporter. In vitro analyses have indicated that ACBP can transport acyl-CoA esters between different enzymatic systems; however, little is known about the in vivo function in mammalian cells. We have generated mice with targeted disruption of ACBP (ACBP(-/-)). These mice are viable and fertile and develop normally. However, around weaning, the ACBP(-/-) mice go through a crisis with overall weakness and a slightly decreased growth rate. Using microarray analysis, we show that the liver of ACBP(-/-) mice displays a significantly delayed adaptation to weaning with late induction of target genes of the sterol regulatory element-binding protein (SREBP) family. As a result, hepatic de novo cholesterogenesis is decreased at weaning. The delayed induction of SREBP target genes around weaning is caused by a compromised processing and decreased expression of SREBP precursors, leading to reduced binding of SREBP to target sites in chromatin. In conclusion, lack of ACBP interferes with the normal metabolic adaptation to weaning and leads to delayed induction of the lipogenic gene program in the liver.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030352PMC
http://dx.doi.org/10.1074/jbc.M110.161109DOI Listing

Publication Analysis

Top Keywords

acbp-/- mice
12
acyl-coa-binding protein
8
acyl-coa esters
8
adaptation weaning
8
target genes
8
delayed induction
8
srebp target
8
weaning
6
disruption acyl-coa-binding
4
protein
4

Similar Publications

An Anticancer Bioactive Peptide Combined with Oxaliplatin Inhibited Gastric Cancer Cells and .

Curr Protein Pept Sci

January 2025

Key Laboratory of Medical Cell Biology in Inner Mongolia, Clinical Medical Research Center, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia,010050, China.

Background: Gastric cancer has become one of the major diseases threatening human health. This study aimed to investigate the mechanism of an anticancer bioactive peptide (ACBP) combined with oxaliplatin (OXA) on MKN-45, SGC7901, and NCI-N87 differentiated human gastric cancer cells and GES-1 immortalized human gastric mucosal epithelial cells. The therapeutic effect and action mechanism of short-term intermittent ACBP combined with OXA on nude mice with human gastric cancer were also investigated.

View Article and Find Full Text PDF

DBI/ACBP is a phylogenetically ancient hormone that stimulates appetite and lipo-anabolism. In response to starvation, DBI/ACBP is secreted through a noncanonical, macroautophagy/autophagy-dependent pathway. The physiological hunger reflex involves starvation-induced secretion of DBI/ACBP from multiple cell types.

View Article and Find Full Text PDF

Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing's syndrome.

Nat Metab

December 2024

Metabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institut, Villejuif, France.

Article Synopsis
  • Cushing's syndrome is linked to high levels of glucocorticoids and is associated with increased plasma levels of ACBP/DBI, which stimulates food intake and fat production.
  • Researchers explored multiple methods to inhibit ACBP/DBI in mice, including genetic modifications and antibody injections, to address Cushing's symptoms.
  • The findings suggest that targeting ACBP/DBI could be an effective strategy for treating Cushing's syndrome and its related complications like obesity and diabetes.
View Article and Find Full Text PDF

Neutralization of the autophagy-repressive tissue hormone DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) enhances anticancer immunosurveillance.

Autophagy

December 2024

Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France.

The plasma concentration of the macroautophagy/autophagy inhibitor DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) increases with aging and body mass index (BMI). Both advanced age and obesity are among the most important risk factors for the development of cancer. We observed that patients with cancer predisposition syndromes due to mutations in , and exhibit abnormally high plasma DBI/ACBP levels.

View Article and Find Full Text PDF
Article Synopsis
  • * Recent studies show that blocking ACBP can make cancer treatments work better, but giving diazepam can cancel out those benefits.
  • * Benzodiazepines like diazepam might weaken the immune response during cancer treatments, which needs more research to understand fully.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!